UPDATE 1-Zynerba’s cannabis-based epilepsy gel fails study, shares plunge

(Adds details, background, shares)

Aug 7 (Reuters) – Zynerba Pharmaceuticals Inc said
on Monday its synthetic cannabis-based gel to treat epilepsy
failed a mid-stage study, sending the U.S. drug developer’s
shares plunging 50 percent.

In the study, two doses of Zynerba’s gel — also its lead
experimental drug — were tested in adults suffering from
epilepsy with partial seizures, those that occur when epileptic
activity takes part in a localized part of the brain.

Neither dose induced a statistically significant improvement
in seizure frequency, when compared to a placebo.

Data from studies evaluating the gel’s use in osteoarthritis
patients and in children with Fragile X Syndrome, a genetic
condition, is expected later this year.

Zynerba’s gel contains a synthetically processed formulation
of cannabidiol (CBD), a non-psychoactive component of the
cannabis plant.

Although many U.S. states have sanctioned the medical or
recreational use of cannabis, drugs derived from the plant could
take longer than usual to hit

... read more at: http://www.businessinsider.com/r-update-1-zynerbas-cannabis-based-epilepsy-gel-fails-study-shares-plunge-2017-8


Leave a Reply

Your email address will not be published. Required fields are marked *